SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea
SciSparc (Nasdaq: SPRC) and Clearmind Medicine have achieved a significant milestone with the publication of their patent application in South Korea for a novel cocaine addiction treatment. The therapy combines Clearmind's MEAI (5-methoxy-2-aminoindane) with SciSparc's PEA (Palmitoylethanolamide).
The patent application is supported by promising preclinical trial results from Bar-Ilan University's Gonda Multidisciplinary Brain Research Center. The research demonstrated that MEAI significantly reduced cocaine-induced craving in animal subjects without affecting their natural reward responses, such as sucrose seeking behavior. This suggests the treatment specifically targets drug-related compulsions while preserving normal reward mechanisms.
This South Korean patent application adds to the companies' existing intellectual property portfolio, which includes multiple applications filed in the United States and other global territories.
SciSparc (Nasdaq: SPRC) e Clearmind Medicine hanno raggiunto un traguardo significativo con la pubblicazione della loro domanda di brevetto in Corea del Sud per un nuovo trattamento della dipendenza da cocaina. La terapia combina il MEAI (5-metossi-2-aminoindano) di Clearmind con il PEA (Palmitoiletanolamide) di SciSparc.
La domanda di brevetto 猫 supportata da promettenti risultati di studi preclinici del Gonda Multidisciplinary Brain Research Center dell'Universit脿 Bar-Ilan. La ricerca ha dimostrato che il MEAI riduce significativamente il desiderio indotto dalla cocaina nei soggetti animali senza influenzare le loro risposte naturali di ricompensa, come il comportamento di ricerca del saccarosio. Ci貌 suggerisce che il trattamento si concentra specificamente sulle compulsioni legate alla droga, preservando i normali meccanismi di ricompensa.
Questa domanda di brevetto in Corea del Sud si aggiunge al portafoglio di propriet脿 intellettuale esistente delle aziende, che include diverse domande presentate negli Stati Uniti e in altri territori globali.
SciSparc (Nasdaq: SPRC) y Clearmind Medicine han alcanzado un hito significativo con la publicaci贸n de su solicitud de patente en Corea del Sur para un nuevo tratamiento de la adicci贸n a la coca铆na. La terapia combina el MEAI (5-metoxi-2-aminoindano) de Clearmind con el PEA (Palmitoiletanolamida) de SciSparc.
La solicitud de patente est谩 respaldada por prometedores resultados de ensayos precl铆nicos del Gonda Multidisciplinary Brain Research Center de la Universidad Bar-Ilan. La investigaci贸n demostr贸 que el MEAI redujo significativamente el deseo inducido por la coca铆na en sujetos animales sin afectar sus respuestas naturales de recompensa, como el comportamiento de b煤squeda de sacarosa. Esto sugiere que el tratamiento se dirige espec铆ficamente a las compulsiones relacionadas con las drogas, preservando los mecanismos de recompensa normales.
Esta solicitud de patente en Corea del Sur se suma al portafolio de propiedad intelectual existente de las empresas, que incluye m煤ltiples solicitudes presentadas en los Estados Unidos y en otros territorios globales.
SciSparc (Nasdaq: SPRC)鞕� Clearmind Medicine鞚� 頃滉淡鞐愳劀 靸堧鞖� 旖旍勾鞚� 欷戨弲 旃橂氩曥棎 雽�頃� 韸鬼棃 於滌洂鞚� 氚滍憸頃橂┌ 欷戩殧頃� 鞚挫爼響滊ゼ 靹胳洜鞀惦媹雼�. 鞚� 旃橂氩曥潃 Clearmind鞚� MEAI(5-氅旐啞鞁�-2-鞎勲雲胳澑雼�)鞕� SciSparc鞚� PEA(韺旊韱犾澕鞐愴儎鞓晞氙鸽摐)毳� 瓴绊暕頃╇媹雼�.
韸鬼棃 於滌洂鞚� 氚旊ゴ鞚茧瀫 雽�頃欔祼鞚� 瓿る嫟 雼ろ暀鞝� 雵� 鞐瓣惮 靹柬劙鞐愳劀鞚� 鞙犽頃� 鞝勳瀯靸� 鞁滍棙 瓴瓣臣鞐� 鞚橅暣 霋冯皼旃惄雼堧嫟. 鞐瓣惮 瓴瓣臣, MEAI電� 霃欕 鞁ろ棙鞐愳劀 旖旍勾鞚胳溂搿� 鞙犽弰霅� 臧堧鞚� 靸侂嫻頌� 欷勳榾鞙茧┌, 鞛愳棸鞝侅澑 氤挫儊 氚橃潙(鞓�: 靹ろ儠 韮愳儔 頄夒彊)鞐愲姅 鞓來枼鞚� 氙胳箻歆� 鞎婌晿鞀惦媹雼�. 鞚措姅 旃橂臧� 鞎诫 甏�霠� 臧曤皶 頄夒彊鞚� 韸轨爼鞝侅溂搿� 瓴儱頃橂┐靹� 鞝曥儊鞝侅澑 氤挫儊 氅旍护雼堨鞚� 氤挫〈頃滊嫟電� 瓴冹潉 鞁滌偓頃╇媹雼�.
鞚� 頃滉淡鞚� 韸鬼棃 於滌洂鞚� 氙戈淡 氚� 旮绊儉 旮�搿滊矊 歆�鞐棎 鞝滌稖霅� 鞐煬 於滌洂鞚� 韽暔頃橂姅 須岇偓鞚� 旮办〈 歆�鞝� 鞛偘 韽姼韽措Μ鞓れ棎 於旉皜霅╇媹雼�.
SciSparc (Nasdaq: SPRC) et Clearmind Medicine ont atteint une 茅tape importante avec la publication de leur demande de brevet en Cor茅e du Sud pour un nouveau traitement de la d茅pendance 脿 la coca茂ne. La th茅rapie combine le MEAI (5-m茅thoxy-2-aminoindane) de Clearmind avec le PEA (Palmito茂l茅thanolamide) de SciSparc.
La demande de brevet est soutenue par des r茅sultats prometteurs d'essais pr茅cliniques du Gonda Multidisciplinary Brain Research Center de l'Universit茅 Bar-Ilan. La recherche a d茅montr茅 que le MEAI r茅duisait significativement le d茅sir induit par la coca茂ne chez les sujets animaux sans affecter leurs r茅ponses naturelles de r茅compense, telles que le comportement de recherche de saccharose. Cela sugg猫re que le traitement cible sp茅cifiquement les compulsions li茅es aux drogues tout en pr茅servant les m茅canismes de r茅compense normaux.
Cette demande de brevet en Cor茅e du Sud s'ajoute au portefeuille de propri茅t茅 intellectuelle existant des entreprises, qui comprend plusieurs demandes d茅pos茅es aux 脡tats-Unis et dans d'autres territoires mondiaux.
SciSparc (Nasdaq: SPRC) und Clearmind Medicine haben einen bedeutenden Meilenstein mit der Ver枚ffentlichung ihres Patentantrags in S眉dkorea f眉r eine neuartige Behandlung von Kokainabh盲ngigkeit erreicht. Die Therapie kombiniert Clearminds MEAI (5-Methoxy-2-Aminoindan) mit SciSparcs PEA (Palmitoylethanolamid).
Der Patentantrag wird durch vielversprechende Ergebnisse aus pr盲klinischen Studien des Gonda Multidisciplinary Brain Research Center der Bar-Ilan-Universit盲t unterst眉tzt. Die Forschung zeigte, dass MEAI das durch Kokain induzierte Verlangen bei Versuchstieren signifikant reduzierte, ohne ihre nat眉rlichen Belohnungsreaktionen, wie das Verhalten bei der Suche nach Saccharose, zu beeinflussen. Dies deutet darauf hin, dass die Behandlung gezielt auf drogenbedingte Zw盲nge abzielt, w盲hrend die normalen Belohnungsmechanismen erhalten bleiben.
Dieser Patentantrag in S眉dkorea erweitert das bestehende Portfolio an geistigem Eigentum der Unternehmen, das mehrere Antr盲ge in den Vereinigten Staaten und anderen globalen Gebieten umfasst.
- Successful preclinical trial results showing reduced cocaine-seeking behavior
- Strategic patent application expansion into South Korean market
- Treatment specifically targets drug addiction without affecting natural reward mechanisms
- Still in preclinical stage, requiring extensive further testing
- No human trial data available yet
TEL AVIV, Israel, March 10, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) has led to the publication of a patent application by the South Korean Intellectual Property Office (鈥淜IPO鈥�). The patent application relates to a combination treatment using Clearmind鈥檚 5-methoxy-2-aminoindane (鈥淢EAI鈥�) and SciSparc鈥檚 Palmitoylethanolamide (鈥淧EA鈥�) for the treatment of cocaine addiction.
The patent is based on preclinical trial results led by Professor Gal Yadid and his team at the Gonda Multidisciplinary Brain Research Center at Bar-Ilan University in Israel. These results followed an earlier experiment in which animals treated with MEAI exhibited a significant reduction in cocaine-induced craving.
Building on these findings, further research assessed whether MEAI鈥檚 effect on drug-seeking behavior extends to natural rewards, as reward-based reinforcement is a fundamental survival mechanism across species. The study produced positive results, demonstrating that while MEAI reduced cocaine-seeking behavior, it did not impair the rats鈥� response to natural rewards, such as sucrose. This suggests that MEAI鈥檚 effect on drug craving is not linked to the general reward system but rather specifically targets drug-related compulsions.
This latest publication adds to multiple patent applications already filed in the U.S. and other global territories as part of the ongoing SciSparc-Clearmind collaboration.
About聽SciSparc聽Ltd. (Nasdaq: SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc鈥檚 focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of ASD and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on Amazon Marketplace.
About聽Clearmind聽Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company鈥檚 intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol 鈥淐WY0.鈥�
For further information visit:聽
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc is using forward-looking statements when it discusses the potential of MEAI鈥檚 effect on drug craving. Because such statements deal with future events and are based on SciSparc's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in SciSparc's Annual Report on Form 20-F filed with the SEC on聽April 1, 2024, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
Investor Contact:
Tel: +972-3-6167055
FAQ
What are the key findings of SciSparc's (SPRC) cocaine addiction treatment trials?
What compounds are used in SciSparc's (SPRC) new cocaine addiction treatment?
Where has SciSparc (SPRC) filed patent applications for its cocaine addiction treatment?
Who conducted the research for SciSparc's (SPRC) cocaine addiction treatment?
